Skip to main content

Duke/UNC ADRC Memory & Aging Study

October 14, 2025
The Memory & Aging Study by the Duke-UNC Alzheimer’s Disease Research Center aim is to pinpoint the biological factors related to both regular brain aging and diseased brain decline. This study works with a large group of younger and older adults, with and without memory problems.

CorEvitas SPHERES Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)

October 14, 2025
The objective of the registry is to create a cohort of patients with NMOSD. This registry will be used for future research, as well as improvements to the diagnosis, treatment, and understanding of NMOSD.

DRPLA Natural History and Biomarkers Study

October 14, 2025
The purpose of this study is to characterize the natural history of DRPLA patients using a variety of clinical and biomarker modalities and to identify genetic factors, biomarkers, and clinical measures that could predict disease progression.

Genetic Determinants of Neurological and Developmental Disorders

October 13, 2025
The purpose of this study is to identify and genomically-characterize individuals with genetically unexplained neurodevelopmental disorders, such as epilepsy. The overarching goal is to provide patients with improved information about the underlying genetic basis of their disorder and illuminate novel genetically-defined treatment approaches in the future.

Post-Acute Symptomatic Seizure Clinic – PASS Clinc

October 13, 2025
The purpose of the study is to identify certain processes following brain injury that may be associated with the risk of developing epilepsy.

Long Term, Observational Registry of Patients with Generalized Myasthenia Gravis Who have Received Treatment with Complement C5 Inhibition Therapies

October 10, 2025
Brief Summary Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®). Detailed Description At the time of enrollment in the Registry, participant records will...

Statins Use in Intracerebral Hemorrhage Patients (SATURN)

October 10, 2025
This is a study being conducted at many sites across the US to evaluate patients who are older than 50 years old, who have sudden bleeding in the brain (intracerebral hemorrhage) while taking a statin medication. It is unclear if continuing to take a statin medication after this type of...

ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

October 10, 2025
The purpose of this study is to evaluate both sporadic (not inherited), and familial (inherited), forms of frontotemporal lobar degeneration (FTLD). Patients include both those who have symptoms of FTLD and those who do not (yet have a family history involving FTLD). This is an observational study, meaning that there...

Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)

October 10, 2025
The ASPIRE trial aims to study anticoagulant medications in patients who have had an intracerebral hemorrhage (bleeding in the brain) who also have atrial fibrillation (irregular heartbeats). Participants who agree to study participation will receive either Aspirin or Apixaban and followed for 12-36 months to see if they have any...

Brain Oxygen Optimization in Severe Traumatic Brain Injury-Phase 3 (BOOST-3)

October 10, 2025
A multicenter, randomized, blinded-endpoint, comparative effectiveness study of goal-directed critical care based upon monitoring of brain tissue oxygen and intracranial pressure versus monitoring of intracranial pressure alone in patients with severe traumatic brain injury. Overview Traumatic brain injury (TBI) is a major cause of death and disability in developed societies....